Pfizer Inc. to Acquire Arena Pharmaceuticals, Inc. – “Creates best-in-class innovative potential therapies for the treatment of immuno-inflammatory diseases”

in Industry Report, Healthcare & Life Sciences on December 23, 2021

Arena Pharmaceuticals, Inc. and Pfizer Inc. have entered into a definitive agreement under which Pfizer will acquire Arena. The boards of directors of both companies have unanimously approved the transaction.

Arena is developing several treatments for gastroenterology, dermatology and cardiology. Its lead candidate, etrasimod, is being tested in a late-stage study in ulcerative colitis, as well as a mid-to-late stage study in Crohn’s disease, both types of inflammatory bowel diseases that cause ulcers in the digestive tract.

Pfizer is also developing a treatment for ulcerative colitis, a chronic and inflammatory bowel disease that affects 3 million people in the United States. The candidate is currently in a mid-stage study, which is expected to be completed by the end of next year.

Executive Summary

• Deal Overview

• Company Overview – Arena Pharmaceuticals, Inc.

• Company Overview – Pfizer Inc..

No of Pages : 64

Release Information

  • Released

    December 23, 2021

  • Last Updated

    December 30, 2021